Danielle Brill
Stock Analyst at Raymond James
(1.90)
# 3,072
Out of 4,761 analysts
75
Total ratings
34.38%
Success rate
-7.24%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Strong Buy | $20 → $52 | $12.96 | +301.23% | 6 | Dec 10, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $65 | $30.84 | +110.80% | 1 | Nov 20, 2024 | |
| DNLI Denali Therapeutics | Reinstates: Market Perform | n/a | $21.59 | - | 1 | Oct 10, 2024 | |
| BMRN BioMarin Pharmaceutical | Reinstates: Outperform | $79 | $68.73 | +14.94% | 1 | Oct 10, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $18 | $7.36 | +144.57% | 1 | Oct 10, 2024 | |
| NBIX Neurocrine Biosciences | Reinstates: Outperform | $155 | $116.11 | +33.49% | 5 | Oct 10, 2024 | |
| IMVT Immunovant | Reinstates: Outperform | $36 | $20.45 | +76.04% | 4 | Oct 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Reinstates: Outperform | $40 | $34.89 | +14.65% | 7 | Oct 10, 2024 | |
| SRPT Sarepta Therapeutics | Reinstates: Outperform | $150 | $108.41 | +38.36% | 3 | Oct 10, 2024 | |
| BIIB Biogen | Reinstates: Market Perform | n/a | $137.08 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $7.15 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $480.33 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $647.49 | -6.56% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $20.29 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $39.38 | +26.97% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $33.75 | +51.11% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $43 | $54.35 | -20.88% | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $0.55 | +809.09% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $50.38 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.77 | - | 5 | Jun 27, 2023 |
uniQure
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $12.96
Upside: +301.23%
Tectonic Therapeutic
Nov 20, 2024
Initiates: Outperform
Price Target: $65
Current: $30.84
Upside: +110.80%
Denali Therapeutics
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $21.59
Upside: -
BioMarin Pharmaceutical
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $68.73
Upside: +14.94%
REGENXBIO
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $7.36
Upside: +144.57%
Neurocrine Biosciences
Oct 10, 2024
Reinstates: Outperform
Price Target: $155
Current: $116.11
Upside: +33.49%
Immunovant
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $20.45
Upside: +76.04%
Harmony Biosciences Holdings
Oct 10, 2024
Reinstates: Outperform
Price Target: $40
Current: $34.89
Upside: +14.65%
Sarepta Therapeutics
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $108.41
Upside: +38.36%
Biogen
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $137.08
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $7.15
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $480.33
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $647.49
Upside: -6.56%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $20.29
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $39.38
Upside: +26.97%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $33.75
Upside: +51.11%
May 10, 2024
Maintains: Outperform
Price Target: $40 → $43
Current: $54.35
Upside: -20.88%
Nov 14, 2023
Maintains: Outperform
Price Target: $9 → $5
Current: $0.55
Upside: +809.09%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $50.38
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.77
Upside: -